These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32319592)

  • 1. Tetramethylpyrazine reduces prostate cancer malignancy through inactivation of the DPP10‑AS1/CBP/FOXM1 signaling pathway.
    Zhou Y; Zhou Z; Ji Z; Yan W; Li H; Yu X
    Int J Oncol; 2020 Jul; 57(1):314-324. PubMed ID: 32319592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.
    Zhou Y; Ji Z; Yan W; Zhou Z; Li H; Xiao Y
    Oncol Rep; 2017 Aug; 38(2):837-842. PubMed ID: 28677763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells.
    Bai T; Liu Y; Li B
    IUBMB Life; 2019 Oct; 71(10):1537-1551. PubMed ID: 31188543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long Noncoding RNA SOX2-OT Knockdown Inhibits Proliferation and Metastasis of Prostate Cancer Cells Through Modulating the miR-452-5p/HMGB3 Axis and Inactivating Wnt/β-Catenin Pathway.
    Song X; Wang H; Wu J; Sun Y
    Cancer Biother Radiopharm; 2020 Nov; 35(9):682-695. PubMed ID: 32407168
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting the FOXM1-regulated long noncoding RNA TUG1 in osteosarcoma.
    Li Y; Zhang T; Zhang Y; Zhao X; Wang W
    Cancer Sci; 2018 Oct; 109(10):3093-3104. PubMed ID: 30099814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition.
    Ketola K; Munuganti RSN; Davies A; Nip KM; Bishop JL; Zoubeidi A
    Clin Cancer Res; 2017 Nov; 23(22):6923-6933. PubMed ID: 28899970
    [No Abstract]   [Full Text] [Related]  

  • 7. INHIBITORY EFFECT OF TETRAMETHYLPYRAZINE ON HEPATOCELLULAR CARCINOMA: POSSIBLE ROLE OF APOPTOSIS AND CELL CYCLE ARREST.
    Cao J; Miao Q; Zhang J; Miao S; Bi L; Zhang S; Yang Q; Zhou X; Zhang M; Xie Y; Wang S
    J Biol Regul Homeost Agents; 2015; 29(2):297-306. PubMed ID: 26122217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXM1-induced upregulation of lncRNA OR3A4 promotes the progression of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.
    Meng H; Zhao B; Wang Y
    Exp Mol Pathol; 2020 Aug; 115():104451. PubMed ID: 32417392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer.
    Ma T; Chen H; Wang P; Yang N; Bao J
    Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162
    [No Abstract]   [Full Text] [Related]  

  • 10. LncRNA PlncRNA-1 accelerates the progression of prostate cancer by regulating PTEN/Akt axis.
    Cui Z; Gao H; Yan N; Dai Y; Wang H; Wang M; Wang J; Zhang D; Sun P; Qi T; Wang Q; Kang W; Jin X
    Aging (Albany NY); 2021 Apr; 13(8):12113-12128. PubMed ID: 33848262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA.
    Shi X; Zhang W; Nian X; Lu X; Li Y; Liu F; Wang F; He B; Zhao L; Zhu Y; Ren S; Sun Y
    Int J Cancer; 2020 Jan; 146(2):475-486. PubMed ID: 31107971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA MFI2-AS1 promotes HCC progression and metastasis by acting as a competing endogenous RNA of miR-134 to upregulate FOXM1 expression.
    Wei Y; Wang Z; Zong Y; Deng D; Chen P; Lu J
    Biomed Pharmacother; 2020 May; 125():109890. PubMed ID: 32106369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA MNX1-AS1 drives aggressive laryngeal squamous cell carcinoma progression and serves as a ceRNA to target FoxM1 by sponging microRNA-370.
    Cui X; Yu H; Yu T; Xiao D; Wang X
    Aging (Albany NY); 2021 Mar; 13(7):9900-9910. PubMed ID: 33882027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly expressed long non-coding RNA FEZF1-AS1 promotes cells proliferation and metastasis through Notch signaling in prostate cancer.
    Zhu LF; Song LD; Xu Q; Zhan JF
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5122-5132. PubMed ID: 31298365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway.
    Shang R; Wang M; Dai B; Du J; Wang J; Liu Z; Qu S; Yang X; Liu J; Xia C; Wang L; Wang D; Li Y
    Mol Oncol; 2020 Jun; 14(6):1381-1396. PubMed ID: 32174012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA MEG3 negatively modified osteosarcoma development through regulation of miR-361-5p and FoxM1.
    Shen B; Zhou N; Hu T; Zhao W; Wu D; Wang S
    J Cell Physiol; 2019 Aug; 234(8):13464-13480. PubMed ID: 30624782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184/c-Myc axis.
    Wang J; Yang X; Li R; Wang L; Gu Y; Zhao Y; Huang KH; Cheng T; Yuan Y; Gao S
    Oncol Rep; 2018 Nov; 40(5):2814-2825. PubMed ID: 30132573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA MCF2L-AS1 aggravates proliferation, invasion and glycolysis of colorectal cancer cells via the crosstalk with miR-874-3p/FOXM1 signaling axis.
    Zhang Z; Yang W; Li N; Chen X; Ma F; Yang J; Zhang Y; Chai X; Zhang B; Hou X; Luo S; Hua Y
    Carcinogenesis; 2021 Feb; 42(2):263-271. PubMed ID: 32860508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional regulation of FoxM1 by HIF‑1α mediates hypoxia‑induced EMT in prostate cancer.
    Tang C; Liu T; Wang K; Wang X; Xu S; He D; Zeng J
    Oncol Rep; 2019 Oct; 42(4):1307-1318. PubMed ID: 31364741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription.
    Liu Y; Liu Y; Yuan B; Yin L; Peng Y; Yu X; Zhou W; Gong Z; Liu J; He L; Li X
    Oncotarget; 2017 Mar; 8(10):17027-17037. PubMed ID: 28199985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.